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ARTICLE
Timing of Antiviral Treatment Initiation is Critical to 
Reduce SARS-CoV-2 Viral Load
Antonio Gonçalves1*, Julie Bertrand1, Ruian Ke2, Emmanuelle Comets1, Xavier de Lamballerie3, Denis Malvy4,5, Andrés Pizzorno6, 
Olivier Terrier6, Manuel Rosa Calatrava6, France Mentré1, Patrick Smith7, Alan S. Perelson2 and Jérémie Guedj1,*
We modeled the viral dynamics of 13 untreated patients infected with severe acute respiratory syndrome-coronavirus 2 to 
infer viral growth parameters and predict the effects of antiviral treatments. In order to reduce peak viral load by more than 
two logs, drug efficacy needs to be > 90% if treatment is administered after symptom onset; an efficacy of 60% could be 
sufficient if treatment is initiated before symptom onset. Given their pharmacokinetic/pharmacodynamic properties, current 
investigated drugs may be in a range of 6–87% efficacy. They may help control virus if administered very early, but may not 
have a major effect in severely ill patients.
The outbreak of severe acute respiratory syndrome corona-
virus 2 (SARS-CoV-2), which originated in Wuhan, China, has 
become a global pandemic. By May 7, 2020, this virus had 
infected more than 3,700,000 people worldwide and caused 
more than 260,000 deaths. To readily propose a first line of 
defense and combat the virus in hospitalized patients, the 
World Health Organization relies on already existing drugs 
(“repurposed”) that are immediately available in large quan-
tities and have a good safety profile. In coordination with 
other European institutions, France is implementing a ran-
domized clinical trial in hospitalized patients (“DisCoVery,” 
NCT04315948) comparing the efficacy of lopinavir/ritona-
vir ± IFN-β-1a, remdesivir, and hydroxychloroquine (HCQ) in 
hospitalized patients. However, the clinical efficacy of cur-
rently available therapies is unknown and could be limited.1
Here, we fit mathematical models of viral dynamics to 
in vivo data to estimate parameters driving viral replication. 
We then use these models to predict the needed efficacy 
of treatments.2 By combining the expected drug concentra-
tions and half-maximal effective concentration (EC50) of drug 
candidates, we also use the model to predict the effects of 
various dosing regimens (doses and timing of treatment initi-
ation) on viral load dynamics.
METHODS
Data used for fitting
We used published data from 13 untreated patients in-
fected with SARS-CoV-2 that were followed in 4 Singapore 
hospitals.3 Patients were hospitalized in median at day 3 
after onset of symptoms (range 1–10 days) and had a me-
dian symptomatic period of 12  days (range 5–24 days). 
Viral loads in nasopharyngeal swabs were measured by 
real-time reverse transcriptase polymerase chain reac-
tion (lower limit of quantification: 38 cycles-threshold, 
CT) at multiple time points with an observed peak of viral 
load at day 5 post onset of symptoms (range 2–27 days). 
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔  Repurposed drugs are being evaluated in clini-
cal trials but little is known about their efficacy on se-
vere acute respiratory syndrome-coronavirus 2 viral  
kinetics.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔  Our study aims to combine pharmacokinetic/pharma-
codynamic and viral kinetics modeling to anticipate the 
effects of lopinavir/ritonavir, hydroxychloroquine (HCQ), 
IFN-β-1a, and remdesivir.
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
✔  Given the predicted efficacy of lopinavir/ritonavir, HCQ, 
IFN-β-1a, and remdesivir, it is unlikely that these drugs will 
have a major effect on viral kinetics if they are adminis-
tered as monotherapy after symptom onset.
HOW MIGHT THIS CHANGE DRUG DISCOVERY, DE-
VELOPMENT, AND/OR THERAPEUTICS?
✔  Our results suggest that these drugs should be evalu-
ated in persons exposed to the virus but prior to appear-
ance of the first symptoms.
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Data presented in CT were transformed to log10 copies/
mL using a published relationship in Zou et al.4 and the 
model was fit to the log10 viral load. Of note, the trans-
formation from CT to log10 copies/mL does not affect the 
estimates of parameters of interest, in particular R0 and 
the death rate of productively infected cells. Time since 
infection was assumed to be 5 days before the onset of 
symptoms.5 In a sensitivity analysis, we also examined 
values of 2 and 10 days.
Model
Viral dynamics was fitted using a target cell limited model 
with an eclipse phase.
The model considers three populations of cells: target 
cells, T, infected cells in the eclipse phase, I1, and produc-
tively infected cells, I2. Given the timescale of the infection, 
we neglect target cell proliferation and natural death, and we 
focused on the process of cell depletion by virus infection. 
We assumed target cells become infected with rate constant 
β. After an average time of 1/k, these cells start producing 
virus and are cleared with per capita rate δ. Virions are re-
leased from productively infected cells I2 at rate p per cell 
and are cleared from the circulation at per capita rate c or lost 
by infecting a target cell. Based on this model, the basic re-
production number, R0, the average number of cells infected 
by a single infected cell at the beginning of the infection, is6,7
To determine the target cell concentration, the following 
calculation was done. We assumed that the total number 
of epithelial cells in the upper respiratory tract was 4 × 108 
cells, distributed in a volume of 30 mL.8 Assuming that 1% 
of these cells express the ACE2 receptor and associated 
proteases needed for viral entry,9 the target cell concentra-
tion, T0, was fixed to 1.33 × 10
5 cells/mL. Following what 
was found in other viral infections, including acute infec-
tion,6 the clearance rate of virus, c, was assumed to be fast 
and equal to 10 day−1 but values of 5 and 20 day−1 were also 
evaluated.
Model building strategy
Because not all parameters can be identified when only viral 
load data are available, parameters V0 and k were fixed at 
10−1 copies/mL and 3 day−1, respectively, which corresponds 
to an initiation of the viral production 8 hours after cell infec-
tion on average.10 A sensitivity analysis was also performed 
with different values of k = {1, 3, 5} day−1 and V0 = {10
−3, 10−2, 
10−1} copies/mL to assess the robustness of the parameter 
estimates. The parameter R0 was estimated instead of the 
infection rate β by a change of variables in Eq. 1.
Parameters were estimated in a nonlinear mixed-effect 
modeling framework using the SAEM algorithm imple-
mented in Monolix (www.lixoft.com). The model providing 
the best description of the data was used for the predictions 
and the individual data fitting, and model averaging was 
used to correct for the model uncertainty when calculating 
confidence intervals of estimated parameters.11
Predicting the effects of treatment according to the 
antiviral efficacy and the time of treatment initiation
We assumed that antivirals with a constant effectiveness ε 
could reduce R0 by a factor (1−ε), with ε taking values from 
50–99% in Eq. 2. We considered different times of treat-
ment initiation, from the time of infection to 3 days after the 
symptom onset. For each treatment strategy, we calculated 
the reduction in viral load at the peak of infection in the ab-
sence of treatment (i.e., 5 days after symptom onset).
Model including an innate immune response
We also examined the possibility that cell infection is limited 
by an innate immune response that renders cells refractory 
to infection, as was proposed for other acute viral infec-
tions.8,12 In this model, two additional compartments are 
added, one for a cytokine (e.g., IFN) released in response 
to antigen, and one representing cells in an antiviral state 
that cannot be infected (Supplementary Information).
Pharmacokinetic/pharmacodynamic drug properties 
of lopinavir/ritonavir, HCQ, IFN-β-1a, and remdesivir
We relied on the literature to find pharmacokinetic (PK) 
population models and parameter values of lopinavir/ri-
tonavir,13 plasma HCQ,14 IFN-β-1a,15 and remdesivir, as well 
as reported EC50 values in vitro (see Table 1). For lopina-
vir EC50, specific results were obtained as follows. Vero 
E6 cells were infected by SARS-CoV-2 (strain BetaCoV/
France/IDF0571/2020) at a multiplicity of infection of 0.01 
and treated with several concentrations of lopinavir 1 hour 
after infection. Supernatant samples were collected at 48 
and 72 hours postinfection. Relative quantification of viral 
genome was performed by real-time quantitative poly-
merase chain reaction RT-qPCR from RNA extracted using 
QIAamp viral RNA Mini Kit (Qiagen). IC50 values of lopinavir 
(5.246 μM and 4.941 μM at 48 and 72 hours postinfection, 
respectively) were calculated from dose-response curve 
using a four-parameter logistic regression model.
To determine the mean antiviral efficacy of these drugs, we 
simulated their plasma PK profiles considering clinical regi-
mens used in the Discovery trial, namely 400–100 mg twice 
daily (b.i.d.) for lopinavir/ritonavir, 400 mg b.i.d. the first day 
(loading dose) followed by 400 mg once daily (q.d.) for HCQ 
and 12 MIU for IFN-β-1a. For each regimen, we simulated 
100 PK profiles according to the reported parameter distri-
butions. Then, we calculated for each simulated individual 
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on total plasma concentrations and did not adjust for plasma 
protein binding when computing efficacy.
Because the PK parameters of remdesivir have not been 
reported yet in humans, the same method could not be ap-
plied. We used the summary statistics reported in the summary 
for compassionate use of remdesivir filed by Gilead to the 
European Medicines Evaluation Agency (EMEA)16 to derive the 
mean concentration of the active metabolite in peripheral blood 
mononuclear cell, mean serum concentration (Cmean), using the 
area under the curve (AUC) after a loading dose of 200 mg and 
after repeated doses of 100 mg q.d., and we assumed that the 
EC50 for the metabolite was equal to the EC50 of the parent.
17
RESULTS
We used a “target-cell limited” model with an eclipse 
phase.8 given by Eq. 1 to characterize the viral load 
dynamics of 13 hospitalized patients in Singapore for which 
data obtained from frequent nasopharyngeal swabs were 
available.3 Because this model needs to incorporate a date 
of infection, an incubation period of 5  days was used as 
the most plausible date of infection in each patient.5 The 
model fitted the data well (Figure 1) and using a model-av-
eraging approach to take into account model uncertainty,11 
the within-host basic reproductive number, R0, was found 
equal to 8.6 (95% confidence interval (CI) = 1.9–17.6), and 
the death rate of productively infected cells was estimated 
as 0.60  day−1 (95% CI  =  0.22–0.97), corresponding to a 
median half-life of 1.2 days (Table 2 and Figure S1). In influ-
enza A, another respiratory infectious disease, estimates of 
the within host R0 varied greatly, but the half-life of infected 
cells was shorter than 10 hours (see more details in ref. 18), 
suggesting a faster clearance of influenza-infected cells 
than SARS-CoV-2. The viral production rate p was also 
Table 1 PK/PD properties of candidate antiviral drugs













Lopinavir/ritonavir Wang et al.13 5.2 μM (unpublished) 400/100 b.i.d. 66%
Hydroxychloroquine Morita et al.14 4.2 μM27 400 mg b.i.d. at D0, followed by 400 mg 
q.d.
6%
IFN-β-1a Hu et al.
15 175 IU/mL29 12 MIU at D0, D2, D5 18%
Remdesivir EMEA guidelines16 1 µM17 200 mg q.d. at D0, followed by 100 mg 
q.d.
87%
We assume that the total concentrations were the driver of efficacy, and we did not consider intracellular metabolites or free drug concentrations.
D, day; EC50, half-maximal effective concentration; EMEA, European Medicines Evaluation Agency; PK/PD, pharmacokinetic/pharmacodynamic.
Figure 1 Individual predictions of severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) of 13 untreated patients from 
Young et al.3
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estimated as 22.7 copies/day (95% CI = 0–59.6; Table 2). 
However, as shown previously, p cannot be uniquely iden-
tified unless the initial target cell density T0 is known.
19,20 
Therefore, the only quantity that can be reliably estimated 
is the product p × T0, equal to 3.0 × 10
6 copies/day (95% 
CI = 0–7.9 × 106]). Parameter estimates and CIs were also 
consistent across models assuming a viral clearance c of 5 
or 20 day−1 (see Table S1).
Our model, along with the parameter estimates given 
above, also inform us both on the time to initiate antiviral 
treatment, and the level of efficacy that needs to be achieved 
to reduce viral load.6 As limited information is available on 
the mechanisms leading to viral clearance, and how they 
may be modulated by treatment, we used our model to 
predict the effects of treatment at day 5 post-symptoms, 
which corresponds to the time the viral load tends to peak 
in the absence of treatment in these data.3 We considered a 
simple case where the drug effectiveness is assumed to be 
constant after therapy initiation (see Methods) and we calcu-
lated the minimal efficacy that would be needed to generate 
more than 2 logs of viral decline at peak viral load in the 
13 studied patients (Figure 2). As predicted by viral kinetic 
modeling theory,2 we found that the impact of treatment on 
peak viral load is inversely correlated with the time of treat-
ment initiation. For a putative treatment blocking the viral 
production p and initiated at the time of infection, symptom 
Table 2 Median and confidence intervals of R0, δ, and p across models and following model averaging procedure
k (day−1) V0 (log10 cp/mL) R0 [95% CI] δ [95% CI] (day
−1) p [95% CI] (day−1)
1 10−1 13.1 [5.1–21.8] 0.68 [0.44–0.9] 26.55 [0–57.32]
10−2 15.4 [7.9–23.2] 0.71 [0.46–0.94] 32 [8.38–56.26]
10−3 19.1 [10.3–28.8] 0.71 [0.46–0.94] 35.18 [12.46–60.06]
3 10−1 8.2 [3.5–13.1] 0.6 [0.38–0.82] 21.36 [0–60.35]
10−2 9.8 [4.1–15.4] 0.58 [0.08–1.15] 20.37 [0–85.01]
10−3 12.5 [4.8–20] 0.58 [0.42–0.74] 23.37 [6.36–39.57]
5 10−1 7.1 [0–13.9] 0.6 [0.19–1.06] 22.07 [0–58.57]
10−2 8.9 [4.7–13.2] 0.57 [0.43–0.74] 22.42 [1.9–41.84]
10−3 10.2 [4.8–16.2] 0.58 [0.46–0.71] 22.31 [5.48–41.46]
Model averaging 8.6 [1.9–17.6] 0.6 [0.22–0.97] 22.71 [0–59.64]
CI, confidence interval.
Figure 2 Reduction in viral load at day 5 post-symptom onset according to the level of antiviral effectiveness of a treatment blocking 
the viral production and the timing of treatment initiation (a) at time of infection; (b) at time of symptom onset; (c) 3days after symptom 
onset). We assumed an incubation period of 5 days.
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onset, or 3 days post-symptom onset, a median efficacy of 
at least 60%, 90%, and 99% in reducing viral replication 
would be needed, respectively, to generate more than 2 logs 
of decline in the peak viral load (Figure 2). The results ob-
tained assuming 2 or 10 days of incubation are presented in 
Figures S2 and S3. We also considered the case of a drug 
like hydroxychloroquine blocking viral infection (parameter 
β in Eq. 1). Results were similar to those obtained before, 
as long as the treatment was initiated before or at symptom 
onset. However, initiating a treatment 3 days post-symptom 
onset could not reduce peak viral load, regardless of the 
drug effectiveness (see Figure S4).
The model, including an innate immune response, did not 
improve the data fitting and, therefore, was not selected for 
inclusion in the main text. However, the same analysis on viral 
dynamics and treatment was conducted and the conclusions 
remained unchanged (see Figures S5, S6 and Table S2).
How do these levels of effectiveness compare with the 
antiviral drugs that are currently being investigated? To 
study this question, we assumed that the treatment antiviral 
effectiveness at time t after treatment initiation,  (t), was re-




(except for remdesivir, see Methods) and the mean antivi-
ral effectiveness during the first 7 days of treatment is given 







du. Given their PK and pharmacody-
namic properties (Table 1), we calculated a mean antiviral 
effectiveness of up to 66% for lopinavir/ritonavir, 6% for 
hydroxychloroquine, 18% for IFN-β-1a, and 87% for remde-
sivir. Given these estimates, these compounds are unlikely to 
have a dramatic effect on peak viral load if administered after 
the onset of symptoms. In fact, the effective concentrations 
will presumably be lower in patients, as drug availability may 
be further limited by protein binding (in particular for lopina-
vir, which has a protein binding rate > 98%) or capability to 
penetrate respiratory compartments. Importantly, levels of 
antiviral efficacy of ~ 50% could nonetheless be relevant in a 
prophylactic setting, before symptom onset, to reduce viral 
replication in the upper respiratory tract and reduce the risk 
of large infiltration to the lungs before an effective immune 
response is mounted to clear the virus.2 Note, above, we 
calculated the effectiveness of drugs administered in mono-
therapy for their usual dosing regimen. We did not consider 
drugs that could directly target infected cells and lead to 
their elimination, such as some monoclonal antibodies.
DISCUSSION
Overall, our results emphasize that the PK/pharmacody-
namic properties of lopinavir/ritonavir, HCQ, IFN-β-1a, and 
remdesivir make them unlikely to have a dramatic impact 
on nasopharyngeal viral load kinetics if they are adminis-
tered after symptom onset. However, these drugs may be 
relevant to reduce viral replication if administered early (i.e., 
as a pre-exposure or post-exposure prophylaxis). This con-
clusion, however, depends on a number of hypotheses that 
we discuss below.
First, we focused on the capability of drugs to reduce the 
peak viral load making the implicit hypothesis that reducing 
peak viral load would likely reduce symptoms and disease 
severity. However, the relationship between viral kinetics and 
disease severity is still debated, with several studies suggest-
ing that viral load did not differ between patients with severe 
and nonsevere disease.21,22 Related to this question, our 
study had some limitations. Our calculations relied on blood 
or plasma drug concentrations. Except for HCQ, for which the 
ratio of lung-to-plasma concentration is known to be high,23,24 
the lung exposure of the other drugs that we considered is 
unknown, and their effect on viral load in the lower respira-
tory tract, as measured from broncho-alveolar aspirates, for 
instance, may differ. In addition, the drug EC50 that we used 
were determined on Vero E6 cells, an in vitro system that may 
not reflect the in vivo EC50. For instance, we found in another 
study that HCQ had no antiviral activity in a more physiologi-
cal model of reconstituted human airway epithelium, and this 
may explain the absence of antiviral of activity of HCQ in vivo 
against SARS-CoV-2.24,25 Finally, we focused solely on the 
antiviral effects of these drugs, and did not consider other 
potential effects of these drugs, such as their immunomod-
ulatory effects. Such effects have been suggested for drugs 
that are not purely antivirals, such as HCQ and IFN-β-1a.26,27
Another implicit implication of our work is the benefit of 
drugs used for prophylaxis (i.e., before exposure to the virus). 
In that case, the objective of the treatment may be to “flatten 
the peak viral load” (by analogy with the now popular terminol-
ogy of epidemiological models) but also to prevent infection. 
Our deterministic, ordinary differential equation-based model, 
cannot reproduce virus extinction, but this can be captured 
using a stochastic version of the same model.28
Our modeling provides estimates of viral kinetic parameters, 
in particular R0 and the loss rate of infected cells, δ, and the 
limit of extrapolation of these parameters also need to be well 
understood. The advantage of studying this series of patients 
was the fact that viral load was sampled extremely frequently 
and early in the infection. However, the number of patients 
we studied was quite small (only 13), and the patients were 
rather young (37 years, range 31–56 years) and may not be 
representative of patients who typically evolve to have severe 
forms of the disease.21 Therefore, more data will be needed 
from various populations to estimate precisely the parameter 
distribution in the population of patients that are most in need 
of antiviral therapy. Finally, our estimate of the loss rate of free 
virus and infected cells are constant over time, which neglects 
the effects of the adaptive immune response. For instance, 
antibodies that emerge in the second week after symptom 
onset,29,30 may contribute to accelerate viral clearance or re-
duce viral infectivity. However, to include these effects would 
require more complex models and quantitative data on these 
antibodies and their in vivo effects, which are currently lacking. 
Further, our analysis of the antiviral effects of repurposed drugs 
focused on their ability to reduce the peak viral load, which 
typically occurs well before the antibody response emerges 
and, hence, the analysis we presented here should not be af-
fected in any major way by our neglect of antibody responses.
Future models of drug efficacy may need to account for viral 
resistance, as it is possible that continued viral replication in 
the presence of drug will select for drug-resistant mutations,31 
although coronaviruses are unusual in that they appear to have 
low mutation rates due to RNA proofreading capability.32 Drug 
combination therapy and more aggressive dosing, including 
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consideration of loading doses to rapidly achieve therapeutic 
exposures, may be beneficial to maximize efficacy of these re-
purposed antiviral agents.33 For all these reasons, the outcome 
of randomized clinical trials remains urgently needed, and the 
analysis of their impacts not only on viral clearance but also on 
disease severity will be critical to design more potent drugs.
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